Independent Radiopharmacy Unit, Faculty of Pharmacy, Medical University of Lublin, PL-20093 Lublin, Poland.
Independent Medical Biology Unit, Faculty of Pharmacy, Medical University of Lublin, PL-20093 Lublin, Poland.
Int J Mol Sci. 2021 Mar 18;22(6):3104. doi: 10.3390/ijms22063104.
A series of thiosemicarbazone derivatives was prepared and their anti-tumor activity in vitro was tested. The X-ray investigation performed for compounds T2, T3 and T5 confirmed the synthesis pathway and assumed molecular structures of analyzed thiosemicarbazones. The conformational preferences of the thiosemicarbazone system were characterized using theoretical calculations by AM1 method. Selected compounds were converted into complexes of Cu (II) ions. The effect of complexing on anti-tumor activity has been investigated. The copper(II) complexes, with Schiff bases T1, T10, T12, T13, and T16 have been synthesized and characterized by chemical and elemental analysis, FTIR spectroscopy and TGA method. Thermal properties of coordination compounds were studied using TG-DTG techniques under dry air atmosphere. G361, A375, and SK-MEL-28 human melanoma cells and BJ human normal fibroblast cells were treated with tested compounds and their cytotoxicity was evaluated with MTT test. The compounds with the most promising anti-tumour activity were then selected and their cytotoxicity was verified with cell cycle analysis and apoptosis/necrosis detection. Additionally, DNA damages in the form of a basic sites presence and the expression of oxidative stress and DNA damage response genes were evaluated. The obtained results indicate that complexation of thiosemicarbazone derivatives with Cu (II) ions improves their antitumor activity against melanoma cells. The observed cytotoxic effect is associated with DNA damage and G2/M phase of cell cycle arrest as well as disorders of the antioxidant enzymes expression.
一系列的缩氨硫脲衍生物被制备出来,并在体外测试了它们的抗肿瘤活性。对于化合物 T2、T3 和 T5 进行的 X 射线研究证实了合成途径和分析的缩氨硫脲的假设分子结构。使用 AM1 方法的理论计算对缩氨硫脲体系的构象偏好进行了表征。选择的化合物被转化为 Cu(II)离子的配合物。研究了络合对抗肿瘤活性的影响。铜(II)配合物,与席夫碱 T1、T10、T12、T13 和 T16 已经通过化学和元素分析、FTIR 光谱和 TGA 方法合成和表征。配位化合物的热性质使用 TG-DTG 技术在干燥空气气氛下进行研究。用测试化合物处理 G361、A375 和 SK-MEL-28 人黑色素瘤细胞和 BJ 人正常成纤维细胞,并通过 MTT 试验评估其细胞毒性。然后选择具有最有前途抗肿瘤活性的化合物,并通过细胞周期分析和凋亡/坏死检测验证其细胞毒性。此外,还评估了以碱基存在形式的 DNA 损伤以及氧化应激和 DNA 损伤反应基因的表达。获得的结果表明,缩氨硫脲衍生物与 Cu(II)离子的络合提高了它们对黑色素瘤细胞的抗肿瘤活性。观察到的细胞毒性效应与 DNA 损伤和 G2/M 期细胞周期阻滞以及抗氧化酶表达紊乱有关。